Analytical & Nonclinical Testing Services

The contract involves the execution of preclinical studies and analytical testing services for influenza vaccine candidates, focusing on critical areas such as toxicology, immunogenicity, potency, and stability assessments to support vaccine development and regulatory submission. These activities are essential for evaluating the safety, biological activity, and consistency of vaccine candidates prior to human trials, ensuring they meet quality and efficacy benchmarks. All work must be conducted in accordance with established scientific and regulatory standards to generate reliable, reproducible data that can inform further advancement of the candidates. The solicitation is designated as a subcontract under NAICS code 541620, with a response deadline of August 15, 2026, and was posted on July 30, 2026. The performance location is identified as Washington, DC, with the contracting agency listed as the Department of Health and Human Services through its Barda - ASPR/DAAPO/Barda DCMA office. While specific award details and point of contact information are not provided, the structure and timing suggest this is part of a broader effort to bolster pandemic preparedness and vaccine readiness under federal public health directives. Respondents are expected to demonstrate technical capability, compliance with nonclinical testing protocols, and experience in vaccine development support.